What is Rachel Rosenstein's NPI number?

Rachel Rosenstein's National Provider Identifier (NPI) is 1871836668, a unique 10-digit ID issued by CMS for use in standard healthcare transactions.

What is Rachel Rosenstein's specialty?

Rachel Rosenstein is listed in the NPPES registry with a primary specialty of Dermatology Physician (Allopathic & Osteopathic Physicians).

Where is Rachel Rosenstein located?

Rachel Rosenstein's practice location on file with NPPES is 30 Prospect Ave, Hackensack, NJ 07601-1915.

What is Rachel Rosenstein's phone number?

The practice phone number listed in the NPPES registry for Rachel Rosenstein is (551) 996-8660.

Does Rachel Rosenstein accept Medicare?

Rachel Rosenstein is approved to bill Medicare according to CMS PECOS enrollment data (2026.04.01). Confirm current participation with the provider before scheduling.

Is Rachel Rosenstein's NPI active?

Yes — Rachel Rosenstein's NPI (1871836668) is active in the NPPES registry as of the last update on 2020-05-26.

IndividualActiveAccepts Medicare

Rachel Rosenstein

NPI 1871836668 · Dermatology Physician · Hackensack, NJ

Rachel Rosenstein is a Dermatology Physician provider in Hackensack, NJ (NPI 1871836668).

Provider details

NPI number: 1871836668
Entity type: Individual
Primary specialty: Dermatology PhysicianAllopathic & Osteopathic Physicians
Sex: Female
Sole proprietor: No
License: 25MA10788500 (NJ)

Practice location

30 Prospect Ave

Hackensack, NJ 07601-1915

Phone: (551) 996-8660

Street-level locationGet directions

More NJ providers

Mailing address

360 Essex St Ste 201

Hackensack, NJ 07601-8566

Specialties & taxonomies

Dermatology PhysicianPrimary207N00000XLicense 25MA10788500 (NJ)
Allopathic & Osteopathic Physicians

Additional practice locations (1)

550 1st Ave
New York, NY 10016-6402
Phone: (212) 263-5506

Enrolled with Medicare as Practitioner - Dermatology · source: CMS PECOS Public Provider Enrollment (2026.04.01)

Profile Score

Established profile(67/100 index)

A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.

Registry tenure25% of score
13 yrs in NPPES registry
Profile completeness25% of score
100% of core fields populated
Practice footprint15% of score
2 documented practice locations
Medicare service volume (vs. specialty peers)25% of score
975 Medicare services, 2024 (ranked within specialty)
Open Payments transparency10% of score
Has Open Payments disclosures (2024)

Medicare volume is ranked against active providers in the same specialty. Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our methodology.

What this provider does (Medicare)

Based on Medicare fee-for-service claims, 2024; not all care is captured.

Service (HCPCS)	Medicare services	Typical Medicare-allowed (2024)
Established Patient Office Or Other Outpatient Visit With Moderate Level of Decision Making, If Using Time, 30 Minutes Or More99214	296	$147
Destruction of Precancer Skin Growth, 2-14 Growths17003	189	$8
Biopsy of Related Skin Growth, First Growth11102	118	$116
Established Patient Office Or Other Outpatient Visit With Low Level OD Decision Making, If Using Time, 20 Minutes Or More99213	118	$102
Biopsy of Related Skin Growth, Each Additional Growth11103	95	$59
Destruction of Precancer Skin Growth, 1 Growth

What this provider prescribes (Medicare Part D)

Top drugs by Medicare Part D claim volume, 2024 · 12 distinct drugs on file.

Drug	Part D claims (2024)	Beneficiaries
Ketoconazole	108	55
Mupirocin	78	63
Hydrocortisone	60	36
Triamcinolone Acetonide	51	30
Clobetasol Propionate	50	32
Fluorouracil	24	15
Fluocinolone Acetonide	19	15
Doxycycline Hyclate	17	—

Transparency — industry payments

Based on CMS Open Payments, 2024; not all care is captured.

$119 across 7 records (Open Payments 2024)

Open Payments discloses payments and transfers of value (meals, travel, consulting, research, royalties) from drug and device makers to providers. This is a transparency signal, not a verdict — such payments are legal and common, and their presence is neither an endorsement nor a criticism. Source: CMS Open Payments, program year 2024.

Enumerated: 2013-04-01
Last updated: 2020-05-26
Certified: 2020-05-26

Frequently asked questions

What is Rachel Rosenstein's NPI number?: Rachel Rosenstein's National Provider Identifier (NPI) is 1871836668, a unique 10-digit ID issued by CMS for use in standard healthcare transactions.
What is Rachel Rosenstein's specialty?: Rachel Rosenstein is listed in the NPPES registry with a primary specialty of Dermatology Physician (Allopathic & Osteopathic Physicians).
Where is Rachel Rosenstein located?: Rachel Rosenstein's practice location on file with NPPES is 30 Prospect Ave, Hackensack, NJ 07601-1915.
What is Rachel Rosenstein's phone number?: The practice phone number listed in the NPPES registry for Rachel Rosenstein is (551) 996-8660.
Does Rachel Rosenstein accept Medicare?: Rachel Rosenstein is approved to bill Medicare according to CMS PECOS enrollment data (2026.04.01). Confirm current participation with the provider before scheduling.
Is Rachel Rosenstein's NPI active?: Yes — Rachel Rosenstein's NPI (1871836668) is active in the NPPES registry as of the last update on 2020-05-26.

Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.

What this provider does (Medicare)

Based on Medicare fee-for-service claims, 2024; not all care is captured.

Service (HCPCS)	Medicare services	Typical Medicare-allowed (2024)
Established Patient Office Or Other Outpatient Visit With Moderate Level of Decision Making, If Using Time, 30 Minutes Or More99214	296	$147
Destruction of Precancer Skin Growth, 2-14 Growths17003	189	$8
Biopsy of Related Skin Growth, First Growth11102	118	$116
Established Patient Office Or Other Outpatient Visit With Low Level OD Decision Making, If Using Time, 20 Minutes Or More99213	118	$102
Biopsy of Related Skin Growth, Each Additional Growth11103	95	$59
Destruction of Precancer Skin Growth, 1 Growth

Drug

Part D claims (2024)

Beneficiaries

Ketoconazole

108

Mupirocin

Hydrocortisone

Triamcinolone Acetonide

Clobetasol Propionate

Fluorouracil

Fluocinolone Acetonide

Doxycycline Hyclate

—

Transparency — industry payments

Based on CMS Open Payments, 2024; not all care is captured.

$119 across 7 records (Open Payments 2024)

Provider details

Practice location

Mailing address

Specialties & taxonomies

Additional practice locations (1)

Profile Score

What this provider does (Medicare)

What this provider prescribes (Medicare Part D)

Transparency — industry payments

Registry dates

Frequently asked questions

Specialties & taxonomies

Additional practice locations (1)

Frequently asked questions

Profile Score

What this provider does (Medicare)

What this provider prescribes (Medicare Part D)

Transparency — industry payments